

Florida Department of Health  
Miami Dade County Health Department Formulary  
HIV Prevention and Rapid Access to Treatment  
Updated 05/21/2021

Correction below made to  
Truvada generic on  
8/25/2022

**Test and Treat (T&T) Formulary – MIAMI-DADE COUNTY**

Rapid access to HIV treatment after an individual is diagnosed is critical. Linkage to a long-term provider should occur no later than 30 days after diagnosis but ideally will happen within seven days.

Below are the medications supported through the Florida Department of Health’s Issuance Program for County Health Departments (CHDs).

**As a payor of last resort, we encourage providers to utilize pharmaceutical samples when possible.**

**FORMULARY**

Brand Name	Generic Name	Therapeutic Class	Pharmacologic Class
<b>BIKTARVY®</b>	bictegravir/emtricitabine/tenofovir alafenamide	antiretroviral	INSTI / NRTI Combo
<b>DESCOVY® + PREZCOBIX®</b>	emtricitabine/tenofovir alafenamide + darunavir/ cobicistat	antiretroviral antiretroviral	NRTI Combo PI/NRTI Combo
<b>DOVATO®</b>	dolutegravir/ lamivudine	antiretroviral	INSTI / NRTI Combo
<b>SYM TUZA®</b>	darunavir/cobicistat/emtricitabine/tenofovir alafenamide	antiretroviral	PI / NRTI Combo
<b>TIVICAY® + DESCOVY®</b>	dolutegravir + emtricitabine/tenofovir alafenamide	antiretroviral antiretroviral	INSTI NRTI Combo
<b>FOR PREGNANT WOMEN or WOMEN OF CHILDBEARING POTENTIAL</b>			
<b>TIVICAY®<sup>1</sup> + TRUVADA®</b>	Dolutegravir + emtricitabine/tenofovir disoproxil fumarate	antiretroviral antiretroviral	INSTI NRTI Combo
<b>TIVICAY® + DESCOVY®</b>	dolutegravir + emtricitabine/tenofovir alafenamide	antiretroviral antiretroviral	INSTI NRTI Combo
<b>PREZISTA® + NORVIR®</b>	darunavir + ritonavir	antiretroviral antiretroviral	PI PI

1. Tivicay® has replaced Isentress as a regimen appropriate and recommended for women at all stages of pregnancy – conception to birth. It may be used with either Truvada or Descovy. The Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission (the Panel) recommends dolutegravir (DTG) as a Preferred antiretroviral (ARV) drug throughout pregnancy and now also recommends DTG as a Preferred ARV for women who are trying to conceive. 2.10.2021

**\*NOTE:** DOVATO® (dolutegravir/lamivudine) has clinical data on use in the T&T scenario (STAT clinical trial). Dovato samples or vouchers can be obtained from ViiV pharmaceutical representatives for use in your clinic. Florida Department of Health cannot be invoiced for this medication.

**\*\*NOTE:** SYMTUZA®; Providers may prescribe this medication, but they must use the voucher provided by Janssen Pharmaceuticals to cover the cost of this medication as the Florida Department of Health cannot be invoiced for this medication.